Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Billings, MT
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Billings, MT
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Albuquerque, NM
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Albany, NY
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Albany, NY
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Armonk, NY
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Armonk, NY
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Greenville, SC
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chattanooga, TN
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Nashville, TN
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dallas, TX
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Tyler, TX
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/20/2018
AOI Pharmaceuticals Investigative Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  2/21/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 2/21/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Intraoperative Imaging of Pulmonary Adenocarcinoma
Intraoperative Imaging of Pulmonary Adenocarcinoma
Status: Enrolling
Updated:  2/28/2018
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Intraoperative Imaging of Pulmonary Adenocarcinoma
Intraoperative Imaging of Pulmonary Adenocarcinoma
Status: Enrolling
Updated: 2/28/2018
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  2/28/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 2/28/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)
STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer
Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer
Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Pembrolizumab in Treating Patients With Malignant Mesothelioma
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Status: Enrolling
Updated:  3/1/2018
University of Chicago
mi
from
Chicago, IL
Pembrolizumab in Treating Patients With Malignant Mesothelioma
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Status: Enrolling
Updated: 3/1/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Afatinib Genomic Landscape
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Status: Enrolling
Updated:  3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Afatinib Genomic Landscape
Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib
Status: Enrolling
Updated: 3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Genomic Landscape of Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Status: Enrolling
Updated:  3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Genomic Landscape of Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Status: Enrolling
Updated: 3/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks
Status: Enrolling
Updated:  3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks
Status: Enrolling
Updated: 3/1/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Retrospective Multi-Center Study to Compare Perioperative Outcomes for Robotic-assisted Lobectomy With Those Associated With VATS and Open Lobectomy for Lung Cancer
A Retrospective Multi-Center Study for Evaluation of Clinical Outcomes With Lobectomy for Lung Cancer
Status: Enrolling
Updated:  3/1/2018
BaylorScott&White
mi
from
Dallas, TX
Retrospective Multi-Center Study to Compare Perioperative Outcomes for Robotic-assisted Lobectomy With Those Associated With VATS and Open Lobectomy for Lung Cancer
A Retrospective Multi-Center Study for Evaluation of Clinical Outcomes With Lobectomy for Lung Cancer
Status: Enrolling
Updated: 3/1/2018
BaylorScott&White
mi
from
Dallas, TX
Click here to add this to my saved trials
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Status: Enrolling
Updated:  3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Status: Enrolling
Updated: 3/2/2018
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Status: Enrolling
Updated:  3/2/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Status: Enrolling
Updated: 3/2/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Understanding Mechanisms of Acquired Resistance to BIBW2992
Understanding Mechanisms of Acquired Resistance to BIBW2992
Status: Enrolling
Updated:  3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Understanding Mechanisms of Acquired Resistance to BIBW2992
Understanding Mechanisms of Acquired Resistance to BIBW2992
Status: Enrolling
Updated: 3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Washington,
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Boston, MA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
New York, NY
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Weston, FL
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Atlanta, GA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Kansas City, KA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Burlington, MA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated:  3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
AUY922 for Advanced ALK-positive NSCLC
A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition
Status: Enrolling
Updated: 3/5/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies
Status: Enrolling
Updated:  3/6/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies
Status: Enrolling
Updated: 3/6/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated:  3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated: 3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Burbank, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Research Site 2
mi
from
Los Angeles, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Research Site 2
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Montebello, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Montebello, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Orange, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials